108 related articles for article (PubMed ID: 1325463)
21. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
[TBL] [Abstract][Full Text] [Related]
22. A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer.
Yamamoto N; Tamura T; Kurata T; Yamamoto N; Sekine I; Kunitoh H; Ohe Y; Saijo N
Cancer Chemother Pharmacol; 2009 Dec; 65(1):79-88. PubMed ID: 19396598
[TBL] [Abstract][Full Text] [Related]
23. A phase I/II trial of combination paclitaxel and carboplatin in advanced or metastatic non-small cell lung cancer: preliminary results of an ongoing study.
Natale RB
Semin Oncol; 1995 Dec; 22(6 Suppl 15):34-7. PubMed ID: 8643968
[TBL] [Abstract][Full Text] [Related]
24. A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer.
Hahn SM; Bernhard EJ; Regine W; Mohiuddin M; Haller DG; Stevenson JP; Smith D; Pramanik B; Tepper J; DeLaney TF; Kiel KD; Morrison B; Deutsch P; Muschel RJ; McKenna WG
Clin Cancer Res; 2002 May; 8(5):1065-72. PubMed ID: 12006520
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
26. A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
Angevin E; Spitaleri G; Rodon J; Dotti K; Isambert N; Salvagni S; Moreno V; Assadourian S; Gomez C; Harnois M; Hollebecque A; Azaro A; Hervieu A; Rihawi K; De Marinis F
Eur J Cancer; 2017 Dec; 87():131-139. PubMed ID: 29145039
[TBL] [Abstract][Full Text] [Related]
27. Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer. CRC Phase II Clinical Trials Committee.
Kaye SB; Brampton M; Harper P; Smyth J; Kerr DJ; Gore M; Green JA; Gilby E; Crawford SM; Rustin GJ
Br J Cancer; 1992 Apr; 65(4):624-5. PubMed ID: 1314072
[TBL] [Abstract][Full Text] [Related]
28. Phase I studies of ZD1839 in patients with common solid tumors.
Lorusso PM
Semin Oncol; 2003 Feb; 30(1 Suppl 1):21-9. PubMed ID: 12644981
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
Lara PN; Koczywas M; Quinn DI; Lenz HJ; Davies AM; Lau DH; Gumerlock PH; Longmate J; Doroshow JH; Schenkein D; Kashala O; Gandara DR
J Thorac Oncol; 2006 Feb; 1(2):126-34. PubMed ID: 17409841
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of retinoic acid and cis-platinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism.
Weisman RA; Christen R; Los G; Jones V; Kerber C; Seagren S; Glassmeyer S; Orloff LA; Wong W; Kirmani S; Howell S
Otolaryngol Head Neck Surg; 1998 May; 118(5):597-602. PubMed ID: 9591856
[TBL] [Abstract][Full Text] [Related]
31. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer.
William WN; Zinner RG; Karp DD; Oh YW; Glisson BS; Phan SC; Stewart DJ
J Thorac Oncol; 2007 Aug; 2(8):745-50. PubMed ID: 17762342
[TBL] [Abstract][Full Text] [Related]
32. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
Metwally MA; Frederiksen KD; Overgaard J
Acta Oncol; 2014 May; 53(5):654-61. PubMed ID: 24328536
[TBL] [Abstract][Full Text] [Related]
33. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
Kurata T; Tamura T; Sasaki Y; Fujii H; Negoro S; Fukuoka M; Saijo N
Jpn J Clin Oncol; 2000 Sep; 30(9):377-84. PubMed ID: 11095134
[TBL] [Abstract][Full Text] [Related]
35. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Specenier P; Rasschaert M; Vroman P; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
Am J Clin Oncol; 2011 Oct; 34(5):472-7. PubMed ID: 20938321
[TBL] [Abstract][Full Text] [Related]
36. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
[TBL] [Abstract][Full Text] [Related]
37. [Chemotherapy with low-dose consecutive cisplatin (CDDP) for patients with recurrent and distant metastasis of head and neck cancer].
Nishino H; Abe K; Igarashi M; Miyata M; Kitamura K
Nihon Jibiinkoka Gakkai Kaiho; 1996 Sep; 99(9):1218-22. PubMed ID: 8914419
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors.
Salazar R; Cortés-Funes H; Casado E; Pardo B; López-Martín A; Cuadra C; Tabernero J; Coronado C; García M; Soto Matos-Pita A; Miguel-Lillo B; Cullell-Young M; Iglesias Dios JL; Paz-Ares L
Cancer Chemother Pharmacol; 2013 Jul; 72(1):75-83. PubMed ID: 23645288
[TBL] [Abstract][Full Text] [Related]
39. Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting.
Shin DM; Holoye PY; Murphy WK; Forman A; Papasozomenos SC; Hong WK; Raber M
Cancer Chemother Pharmacol; 1991; 29(2):145-9. PubMed ID: 1662119
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination.
O'Dwyer PJ; Cornfeld MJ; Peter R; Comis RL
Cancer Chemother Pharmacol; 1990; 27(2):131-4. PubMed ID: 2249328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]